Skip NavigationSkip to Content
Return Return to Search Results

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma

  1. Author:
    Thomopoulos, Thomas P
    Rosati,Margherita
    Terpos, Evangelos [ORCID]
    Stellas, Dimitris [ORCID]
    Hu, Xintao [ORCID]
    Karaliota, Sevasti [ORCID]
    Bouchla, Anthi
    Katagas, Ioannis
    Antoniadou, Anastasia [ORCID]
    Mentis, Andreas
    Papageorgiou, Sotirios G [ORCID]
    Politou, Marianna
    Bear,Jenifer [ORCID]
    Donohue,Duncan
    Kotanidou, Anastasia [ORCID]
    Kalomenidis, Ioannis [ORCID]
    Korompoki, Eleni
    Burns,Robert
    Pagoni, Maria
    Grouzi, Elisavet
    Labropoulou, Stavroula
    Stamoulis, Kostantinos
    Bamias, Aristotelis [ORCID]
    Tsiodras, Sotirios
    Dimopoulos, Meletios-Athanasios [ORCID]
    Pavlakis,George [ORCID]
    Pappa, Vasiliki
    Felber,Barbara

  2. Author Address

    Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA., Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA., Frederick National Laboratory for Cancer Research, Basic Science Program, Frederick, MD 21701, USA., Fourth Department of Internal Medicine, School of Medicine, University General Hospital "Attikon", National and Kapodistrian University of Athens, 11527 Athens, Greece., National Influenza Reference Laboratory of Southern Greece, Hellenic Pasteur Institute, 11521 Athens, Greece., Hematology Laboratory-Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., MS Applied Information and Management Sciences, Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA., First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece., BMT Unit, Haematology-Lymphomas Department, Evangelismos Hospital, 10676 Athens, Greece., Transfusion Service and Clinical Hemostasis of Saint Savvas, Oncology Hospital of Athens, 11522 Athens, Greece., Hellenic National Blood Transfusion Center, 13678 Athens, Greece.,
    1. Year: 2021
    2. Date: 09 15
    3. Epub Date: 2021 09 15
  2. Journal: Viruses
    1. 13
    2. 9
  4. Type of Article: Article
  5. Article Number: 1844
  6. ISSN: 1999-4915
  1. Abstract:

    COVID-19 is an ongoing pandemic with high morbidity and mortality. Despite meticulous research, only dexamethasone has shown consistent mortality reduction. Convalescent plasma (CP) infusion might also develop into a safe and effective treatment modality on the basis of recent studies and meta-analyses; however, little is known regarding the kinetics of antibodies in CP recipients. To evaluate the kinetics, we followed 31 CP recipients longitudinally enrolled at a median of 3 days post symptom onset for changes in binding and neutralizing antibody titers and viral loads. Antibodies against the complete trimeric Spike protein and the receptor-binding domain (Spike-RBD), as well as against the complete Nucleocapsid protein and the RNA binding domain (N-RBD) were determined at baseline and weekly following CP infusion. Neutralizing antibody (pseudotype NAb) titers were determined at the same time points. Viral loads were determined semi-quantitatively by SARS-CoV-2 PCR. Patients with low humoral responses at entry showed a robust increase of antibodies to all SARS-CoV-2 proteins and Nab, reaching peak levels within 2 weeks. The rapid increase in binding and neutralizing antibodies was paralleled by a concomitant clearance of the virus within the same timeframe. Patients with high humoral responses at entry demonstrated low or no further increases; however, virus clearance followed the same trajectory as in patients with low antibody response at baseline. Together, the sequential immunological and virological analysis of this well-defined cohort of patients early in infection shows the presence of high levels of binding and neutralizing antibodies and potent clearance of the virus.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/v13091844
  3. PMID: 34578426
  4. View record in Web of Science®
  5. WOS: 000699917400001
  6. PII : v13091844

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel